Trial
NCT01384162
An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Newron Sweden AB
Collaborators
Medtronic; ICON Clinical Research
Condition
Amyotrophic Lateral Sclerosis
Intervention
sNN0029
Why stopped
Issues with development and supply of infusion system for delivery of IMP. Lack of favorable benefit risk ratio in sNN0029-003 study (review of interim data).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-01-27